Chronic myelogenous leukemia

Susan O'Brien; Ellin Berman; Kapil Bhalla; Edward A. Copelan; Marcel P. Devetten; Peter D. Emanuel; Harry P. Erba; Peter L. Greenberg; Joseph O. Moore; Donna Przepiorka; Jerald P. Radich; Russell J. Schilder; Paul Shami; B. Douglas Smith; David S. Snyder; Robert J. Soiffer; Martin S. Tallman; Moshe Talpaz; Meir Wetzler

doi:10.6004/jnccn.2007.0043

Chronic myelogenous leukemia

Susan O'Brien^*, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P. Devetten, Peter D. Emanuel, Harry P. Erba, Peter L. Greenberg, Joseph O. Moore, Donna Przepiorka, Jerald P. Radich, Russell J. Schilder, Paul Shami, B. Douglas Smith, David S. Snyder, Robert J. Soiffer, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

Original language	English (US)
Pages (from-to)	474-496
Number of pages	23
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	5
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2007.0043
State	Published - May 2007
Externally published	Yes

Keywords

Chronic myelogenous leukemia
Desatinib
Imatinib
Karyotyping
NCCN clinical practice guidelines
Polymerase chain reaction
Transplantation

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2007.0043

Cite this

O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiorka, D., Radich, J. P., Schilder, R. J., Shami, P., Smith, B. D., Snyder, D. S., Soiffer, R. J., Tallman, M. S., Talpaz, M., & Wetzler, M. (2007). Chronic myelogenous leukemia. JNCCN Journal of the National Comprehensive Cancer Network, 5(5), 474-496. https://doi.org/10.6004/jnccn.2007.0043

@article{5c20caf4363d4120b60e04f8a081a006,

title = "Chronic myelogenous leukemia",

abstract = "Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.",

keywords = "Chronic myelogenous leukemia, Desatinib, Imatinib, Karyotyping, NCCN clinical practice guidelines, Polymerase chain reaction, Transplantation",

author = "Susan O'Brien and Ellin Berman and Kapil Bhalla and Copelan, {Edward A.} and Devetten, {Marcel P.} and Emanuel, {Peter D.} and Erba, {Harry P.} and Greenberg, {Peter L.} and Moore, {Joseph O.} and Donna Przepiorka and Radich, {Jerald P.} and Schilder, {Russell J.} and Paul Shami and Smith, {B. Douglas} and Snyder, {David S.} and Soiffer, {Robert J.} and Tallman, {Martin S.} and Moshe Talpaz and Meir Wetzler",

year = "2007",

month = may,

doi = "10.6004/jnccn.2007.0043",

language = "English (US)",

volume = "5",

pages = "474--496",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

O'Brien, S, Berman, E, Bhalla, K, Copelan, EA, Devetten, MP, Emanuel, PD, Erba, HP, Greenberg, PL, Moore, JO, Przepiorka, D, Radich, JP, Schilder, RJ, Shami, P, Smith, BD, Snyder, DS, Soiffer, RJ, Tallman, MS, Talpaz, M & Wetzler, M 2007, 'Chronic myelogenous leukemia', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 5, pp. 474-496. https://doi.org/10.6004/jnccn.2007.0043

TY - JOUR

T1 - Chronic myelogenous leukemia

AU - O'Brien, Susan

AU - Berman, Ellin

AU - Bhalla, Kapil

AU - Copelan, Edward A.

AU - Devetten, Marcel P.

AU - Emanuel, Peter D.

AU - Erba, Harry P.

AU - Greenberg, Peter L.

AU - Moore, Joseph O.

AU - Przepiorka, Donna

AU - Radich, Jerald P.

AU - Schilder, Russell J.

AU - Shami, Paul

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Soiffer, Robert J.

AU - Tallman, Martin S.

AU - Talpaz, Moshe

AU - Wetzler, Meir

PY - 2007/5

Y1 - 2007/5

N2 - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

AB - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

KW - Chronic myelogenous leukemia

KW - Desatinib

KW - Imatinib

KW - Karyotyping

KW - NCCN clinical practice guidelines

KW - Polymerase chain reaction

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=34249288276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249288276&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2007.0043

DO - 10.6004/jnccn.2007.0043

M3 - Review article

C2 - 17509252

AN - SCOPUS:34249288276

SN - 1540-1405

VL - 5

SP - 474

EP - 496

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Chronic myelogenous leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this